NZ735777A - Methods and compositions to inhibit symptoms associated with veisalgia - Google Patents

Methods and compositions to inhibit symptoms associated with veisalgia

Info

Publication number
NZ735777A
NZ735777A NZ735777A NZ73577716A NZ735777A NZ 735777 A NZ735777 A NZ 735777A NZ 735777 A NZ735777 A NZ 735777A NZ 73577716 A NZ73577716 A NZ 73577716A NZ 735777 A NZ735777 A NZ 735777A
Authority
NZ
New Zealand
Prior art keywords
symptoms associated
veisalgia
compositions
methods
inhibit symptoms
Prior art date
Application number
NZ735777A
Other languages
English (en)
Inventor
Jacqueline Iversen
James Iversen
Original Assignee
Jacqueline M Iversen
James M Iversen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacqueline M Iversen, James M Iversen filed Critical Jacqueline M Iversen
Publication of NZ735777A publication Critical patent/NZ735777A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NZ735777A 2015-03-26 2016-03-18 Methods and compositions to inhibit symptoms associated with veisalgia NZ735777A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562138665P 2015-03-26 2015-03-26
PCT/US2016/023200 WO2016154028A1 (en) 2015-03-26 2016-03-18 Methods and compositions to inhibit symptoms associated with veisalgia

Publications (1)

Publication Number Publication Date
NZ735777A true NZ735777A (en) 2023-03-31

Family

ID=56976188

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ735777A NZ735777A (en) 2015-03-26 2016-03-18 Methods and compositions to inhibit symptoms associated with veisalgia

Country Status (15)

Country Link
US (3) US10420756B2 (enExample)
EP (2) EP3973957A1 (enExample)
JP (1) JP6851365B2 (enExample)
KR (1) KR102597910B1 (enExample)
CN (2) CN107635549A (enExample)
AU (1) AU2016235484B2 (enExample)
BR (1) BR112017020307B1 (enExample)
CA (1) CA2980162C (enExample)
ES (1) ES2926494T3 (enExample)
IL (1) IL254641B2 (enExample)
MX (2) MX390011B (enExample)
NZ (1) NZ735777A (enExample)
PL (1) PL3273952T3 (enExample)
WO (1) WO2016154028A1 (enExample)
ZA (1) ZA201706794B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635549A (zh) 2015-03-26 2018-01-26 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
WO2018232260A1 (en) 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit symptoms associated with viral upper respiratory tract infections
WO2019046201A1 (en) * 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION
WO2019055941A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING OPIOID DEPENDENCE
WO2019055942A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING OPIOID TOLERANCE
WO2019055939A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING SYMPTOMS ASSOCIATED WITH OPIOID WEANING
WO2019178516A1 (en) * 2018-03-16 2019-09-19 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075426A (en) 1976-03-12 1978-02-21 Harvey Mitchell Gould Parallel silent communicator
US4496548A (en) * 1983-02-04 1985-01-29 Moldowan Mervin J Composition and method for reducing hangover
US5053396A (en) 1985-08-27 1991-10-01 Blass David H Therapeutic composition
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
AU8764191A (en) 1990-09-28 1992-04-28 Mcneill-Ppc Inc. Ibuprofen-antihistamine combinations
RU2167657C2 (ru) * 1992-08-03 2001-05-27 Сепракор, Инк. Фармацевтическая композиция для лечения аллергических заболеваний, способ антигистаминного лечения, применение композиции для получения лекарственного препарата
DE69629989T2 (de) 1995-04-21 2004-07-22 Sekisui Kagaku Kogyo K.K. Präparate zur äusserlichen anwendung zur behandlung von dermatosen
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
DE19708209C2 (de) 1997-02-28 2000-03-02 Hans Juergen Pauling Wiederaufladbare Batterieanordnung und deren Verwendung
US20050281751A1 (en) 1997-07-21 2005-12-22 Bruce Levin Directed intranasal administration of pharmaceutical agents
CN1278728A (zh) * 1997-09-19 2001-01-03 普罗克特和甘保尔公司 治疗呼吸系统疾病的组合物和方法
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US20030181495A1 (en) 1998-06-23 2003-09-25 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6697361B2 (en) 1998-09-15 2004-02-24 Nortel Networks Limited Method and apparatus for stream aggregation in a multiprotocol label switching network environment
US6274627B1 (en) 1999-10-12 2001-08-14 Medinox, Inc. Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
WO2003009834A1 (en) 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
US20020045184A1 (en) * 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
US20050009730A1 (en) 2001-10-16 2005-01-13 Dale Edgar Treatment of cns disorders using cns target modulators
US7189757B2 (en) 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
GB0128674D0 (en) 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
AU2003210598A1 (en) 2002-01-18 2003-09-04 Hypnion Inc Treatment of sleep disorders using sleep target modulators
DE10223147A1 (de) * 2002-05-16 2003-11-27 Newfrey Llc Fügesystemkopf, Fügesystem und Verfahren zum Zuführen und Fügen von Elementen
WO2004016268A1 (en) * 2002-08-15 2004-02-26 Tan Oon T Composition and method for controlling alcohol-induced facial flushing in susceptible humans
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
TWI313598B (en) * 2002-12-18 2009-08-21 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
GB0312425D0 (en) 2003-05-30 2003-07-09 Boots Co Plc Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith
GB0312419D0 (en) 2003-05-30 2003-07-02 Boots Healthcare Int Ltd Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess
US20070292498A1 (en) 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
US20080021083A1 (en) * 2004-03-03 2008-01-24 Daley Thomas E 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
GB2435410B (en) * 2004-04-21 2007-12-05 Silent Gliss Internat Ltd Improvements in or relating to curtain heading systems
ATE529133T1 (de) 2004-08-18 2011-11-15 Medrx Co Ltd Topisches präparat
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
EP1804804B1 (en) 2004-09-21 2012-01-25 Hypnion, Inc. 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS
US7563785B2 (en) 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
WO2006064747A1 (ja) 2004-12-15 2006-06-22 Saitama Daiichi Pharmaceutical Co., Ltd. 医療用テープ剤
ES2510690T3 (es) 2004-12-17 2014-10-21 Alan B. Cash Método para extender la esperanza de vida y retrasar la aparición de enfermedad relacionada con la edad
CA2597525A1 (en) 2005-02-17 2006-08-24 Senju Pharmaceutical Co., Ltd. Solid ophthalmic drug for external use
US20070093520A1 (en) 2005-04-15 2007-04-26 Caras Steven D Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject
US20070086974A1 (en) * 2005-10-06 2007-04-19 Gawande Rahul S Cetirizine compositions
US20070196518A1 (en) 2005-12-15 2007-08-23 Karol Wojewnik Composition and Method for Mitigating a Negative Effect of Alcohol Consumption
WO2007092334A1 (en) 2006-02-02 2007-08-16 Hypnion, Inc. Method of treating sleep disorders
WO2007092333A1 (en) 2006-02-03 2007-08-16 Hypnion, Inc. Use of olopatadine for treating sleep disorders
GB2435418A (en) 2006-02-28 2007-08-29 Amalan Selvarajah Composition for preventing and alleviating alcohol hangover
US20070224128A1 (en) 2006-03-07 2007-09-27 Donn Michael Dennis Drug adherence monitoring system
US20080131532A1 (en) 2006-10-17 2008-06-05 Lorn Leitman Fast asleep
MX2009004439A (es) * 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
MX2009006672A (es) 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
WO2008095086A2 (en) 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
JP2010537990A (ja) 2007-08-27 2010-12-09 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ
US20090156982A1 (en) 2007-09-06 2009-06-18 Arezou Petrie Transdermal treatment device and method
MX2010004265A (es) 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
EP3090739A1 (en) * 2008-01-04 2016-11-09 Schabar Research Associates LLC Compositions composed of naproxen sodium and nizatidine
WO2009094177A1 (en) * 2008-01-24 2009-07-30 Raptor Therapeutics Inc. Protopanaxadiol-type ginsenoside compositions and uses thereof
US20090258869A1 (en) 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
KR20100127799A (ko) 2008-02-28 2010-12-06 유니버시티 오브 버지니아 페이턴트 파운데이션 세로토닌 운반체 유전자 및 알콜중독의 치료
KR20110017365A (ko) * 2008-05-30 2011-02-21 페어필드 클리니컬 트라이얼즈 엘엘씨 피부 염증 및 변색을 위한 방법 및 조성물
AU2009260166B2 (en) 2008-06-20 2014-10-09 Alphapharm Pty Ltd Pharmaceutical formulation
US20130029970A1 (en) 2009-07-10 2013-01-31 Ironwood Pharmaceuticals, Inc CB Receptor Agonists
WO2011006073A1 (en) 2009-07-10 2011-01-13 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
US20130109721A1 (en) 2009-12-08 2013-05-02 Ironwood Pharmaceuticals, Inc. FAAH Inhibitors
JP6200648B2 (ja) 2009-12-18 2017-09-20 アケリオス セラピューティクス，インコーポレーテッド 三叉神経・自律神経性頭痛、片頭痛、および血管症状の治療および予防のための組成物
WO2011100359A1 (en) 2010-02-09 2011-08-18 Ironwood Pharmaceuticals, Inc. Cannabinoid agonists
US20130196960A1 (en) 2010-02-09 2013-08-01 Ironwood Pharmaceuticals, Inc. Cannabinoid Receptor Agonists
WO2012048294A2 (en) 2010-10-07 2012-04-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012088431A1 (en) 2010-12-23 2012-06-28 Ironwood Pharmaceuticals, Inc. Faah inhibitors
EP2680828A4 (en) 2011-02-28 2014-07-30 Technologies Khlôros Inc COUGAR MEANS FOR ORAL ABSORPTION
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
US9161957B2 (en) 2012-08-03 2015-10-20 Life Well Lived, Llc Compositions and methods for reducing blood alcohol content
JP6276944B2 (ja) * 2013-08-29 2018-02-07 興和株式会社 フェキソフェナジンとｎｓａｉｄ含有医薬組成物
US20150132410A1 (en) * 2013-11-14 2015-05-14 Michael M. Jacobs Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome
CN107635549A (zh) 2015-03-26 2018-01-26 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
WO2019178516A1 (en) * 2018-03-16 2019-09-19 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis

Also Published As

Publication number Publication date
MX2022001796A (es) 2022-03-17
CN115887456A (zh) 2023-04-04
BR112017020307A2 (en) 2018-06-05
AU2016235484B2 (en) 2021-02-18
JP6851365B2 (ja) 2021-03-31
EP3273952A4 (en) 2018-11-21
CA2980162A1 (en) 2016-09-29
KR20170131647A (ko) 2017-11-29
JP2018509470A (ja) 2018-04-05
WO2016154028A1 (en) 2016-09-29
EP3973957A1 (en) 2022-03-30
IL254641B1 (en) 2023-09-01
MX390011B (es) 2025-03-20
CA2980162C (en) 2024-06-18
BR112017020307B1 (pt) 2023-11-07
AU2016235484A1 (en) 2017-10-12
IL254641A0 (en) 2017-11-30
MX2017012132A (es) 2018-07-06
IL254641B2 (en) 2024-01-01
ES2926494T3 (es) 2022-10-26
US20200009119A1 (en) 2020-01-09
ZA201706794B (en) 2019-02-27
PL3273952T3 (pl) 2022-11-14
CN107635549A (zh) 2018-01-26
US20160279112A1 (en) 2016-09-29
US20230064685A1 (en) 2023-03-02
US11464766B2 (en) 2022-10-11
EP3273952B1 (en) 2022-06-15
US10420756B2 (en) 2019-09-24
KR102597910B1 (ko) 2023-11-02
EP3273952A1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
ZA202308496B (en) Pharmaceutical compositions of therapeutically active compounds
MX2017012132A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
NI201600071A (es) Compuestos de inhibidor de autotaxina
HK1247850A1 (zh) Pd-1 拮抗剂与egfr 抑制剂的组合
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
HK1231390A1 (zh) 用於局部给药的药用组合物
PH12015501783B1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
IN2013MU02370A (enExample)
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
UY35748A (es) Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple
TW201611830A (en) Pharmaceutical formulation for reducing bladder spasms and method of use thereof
PH12020500472A1 (en) Autotaxin inhibitor compounds
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
IN2014DE00822A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2025 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20240219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2026 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20250309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2027 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20260305